Skip to main content
Clinical Trials/NCT00764803
NCT00764803
Terminated
Not Applicable

Post-Market Study: The Efficacy of the 3DKnee™ System vs. the MJS Knee System

Encore Medical, L.P.1 site in 1 country27 target enrollmentJanuary 2008

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Rheumatoid Arthritis
Sponsor
Encore Medical, L.P.
Enrollment
27
Locations
1
Primary Endpoint
The survivorship and efficacy of the Encore 3DKnee™ system with that of the Encore MJS™ Knee System
Status
Terminated
Last Updated
16 years ago

Overview

Brief Summary

The purpose of this study is to compare the survivorship and efficacy of the Encore 3DKnee™ system with that of the Encore MJS™ Knee System in a group of 600 patients for whom data collection is already under way.

Detailed Description

The purpose of this study is to compare the survivorship and efficacy of the Encore 3DKnee™ system with that of the Encore MJS™ Knee System in a group of 600 patients for whom data collection is already under way. Approximately 300 patients have already received the MJS™ knee system and data, as described below, has been collected for these patients over a period of two years. A second group of 300 patients will receive the Encore 3DKnee™ system over the next two years, and equivalent data will be collected for these individuals. A portion of the data has been collected over the past year, and now we would like to obtain permission from the patients to analyze these data as well as collect an additional year of data.

Registry
clinicaltrials.gov
Start Date
January 2008
End Date
December 2009
Last Updated
16 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • This must be a primary knee replacement on this knee.
  • Patient is over 18 years of age or older
  • Patients must have one of the following
  • rheumatoid or traumatic arthritis OR
  • joint disease secondary to osteoarthritis
  • Patient is likely to be available for evaluation for the duration of the study
  • Able and willing to sign the informed consent and follow study procedures
  • Patient is not pregnant

Exclusion Criteria

  • Is younger than 18 years of age
  • If there has been a total knee replacement on this knee in the past (no revisions allowed in study)
  • Overt infection
  • Alcoholism or other addictions
  • Muscular, neurological or vascular deficiencies which compromise the affected extremity
  • Marked bone loss
  • Materials sensitivity
  • Mental conditions that may interfere with the patient's ability to give an informed consent or willingness to fulfill the study requirements
  • Patient is pregnant

Outcomes

Primary Outcomes

The survivorship and efficacy of the Encore 3DKnee™ system with that of the Encore MJS™ Knee System

Time Frame: 2 year

Study Sites (1)

Loading locations...

Similar Trials

Active, not recruiting
Phase 1
Estudio de fase III para evaluar la eficacia y la seguridad de docetaxel y prednisona con o sin lenalidomida en pacientes con cáncer de próstata resistente a la castración (CPRC).A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCERPacientes con cáncer de próstata metastásico sin experiencia de quimioterapia y con elevación documentada del antígeno prostático específico (PSA) o enfermedad progresiva (EP) documentada después de tratamiento hormonal.Chemo-naïve metastatic prostate cancer subjects with documented rising Prostate Specific Antigen (PSA) or documented Progressive Disease (PD) following hormonal therapyMedDRA version: 12.0Level: PTClassification code 10036909Term: Prostate cancer metastatic
EUCTR2008-007969-23-ESCelgene Corporation1,015
Active, not recruiting
Phase 1
A phase 3 Study to Evaluate the Efficacy and Safety of SHR0302 in Ulcerative Colitis.Moderately to severely active Ulcerative Colitis (UC)MedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
EUCTR2021-001940-86-PLReistone Biopharma Company Limited368
Active, not recruiting
Phase 1
Treatment of infectious diseases and disorders affecting the female sex organs;
EUCTR2016-002808-19-PLAziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.p.A.440
Active, not recruiting
Phase 1
Treatment of infectious diseases and disorders affecting the female sex organs.ncomplicated vulvovaginal candidosis (VVC)MedDRA version: 20.1Level: LLTClassification code 10047783Term: Vulvovaginal candidaSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
EUCTR2016-002808-19-ITAZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.440
Active, not recruiting
Phase 1
Treatment of infectious diseases and disorders affecting the female sex organs;ncomplicated vulvovaginal candidosis (VVC)MedDRA version: 20.0 Level: LLT Classification code 10047783 Term: Vulvovaginal candida System Organ Class: 100000054373Therapeutic area: Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
EUCTR2016-002808-19-BGA.C.R.A.F. S.p.A. (Aziende Chimiche Riunite Angelini Francesco)445